Here are five things to know about the IPO:
1. The company submitted a confidential draft to the Securities and Exchange Commission in August and another revised registration statement in September. Companies with revenue under $1 billion can keep filings confidential until they’re ready to market shares under the JOBS Act of 2012.
2. Nevro submitted a premarket approval application to the FDA in June for their pain relief system.
3. The company hopes for a commercial launch of the pain system by early 2016, pending FDA approval.
4. In 2008, Nevro raised $22 million and then Johnson & Johnson Development Corp., led another financing round with $58 million in 2011. J&J Development also participated in a 2013 round of financing that reached $48 million.
5. J.P. Morgan and Morgan Stanley are joint book-running managers for the IPO.
6. Nevro plans to raise $115 million in the IPO currently, but that number will likely change. The company is listed on the New York Stock Exchange under NVRO.
More articles on orthopedic devices:
Amedica appoints Eric Stookey to board of directors
5 robotic spine surgery systems sold in the United States for 3Q
Across the Atlantic: 5 key observations on Asia orthobiologics market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
